SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: billy d who wrote (224)7/15/1997 11:56:00 AM
From: Biomaven   of 10280
 
Billy -

I've had the same reaction from a couple of pediatricians I've discussed this with.

Here's my sales pitch:

"Doctor, you effectively have a choice between prescribing Levalbuterol and prescribing _two_ drugs, Levalbuterol and D-albuterol(?). Now D-albuterol has immediate side-effects, has no beneficial effect that we know of, and indeed is associated with long-term decline in lung function. Why on earth would you want to give it to your patients?"

I think that where it is simply a side-effect issue, the conclusion is less clear. Thus we see the cheaper fenfluramine continuing to be prescribed (in conjunction with phentermine, which counteracts some of the side-effects) even though dexfenfluramine has fewer side effects. However, when you have both fewer side-effects and better efficacy, it is hard for me to see a doctor sticking with the old drug unless cost considerations are completely paramount.

Peter

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News